Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in ESRD and HFrEF
NCT06249932Phase 4Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by National Taiwan University Hospital. Started Mar 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06249932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249932.